News headlines about PerkinElmer (NYSE:PKI) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. PerkinElmer earned a news sentiment score of 0.22 on Accern’s scale. Accern also assigned news headlines about the medical research company an impact score of 46.0724054665191 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern’s scoring:
- PerkinElmer to Hold Earnings Call on Monday, April 30, 2018 (finance.yahoo.com)
- BRIEF-PerkinElmer Prices Offering Of Euro Denominated Senior Notes (reuters.com)
- Parent Project Muscular Dystrophy Selects PerkinElmer to Support Decode Duchenne Program (businesswire.com)
- PerkinElmer prices euro debt offering (seekingalpha.com)
- Contrasting PerkinElmer (PKI) & Bio-Rad Laboratories (BIO) (americanbankingnews.com)
A number of research firms have recently issued reports on PKI. ValuEngine upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating in a research note on Monday. Zacks Investment Research cut shares of PerkinElmer from a “buy” rating to a “hold” rating in a research note on Tuesday, March 20th. Barclays lifted their target price on shares of PerkinElmer from $69.00 to $73.00 and gave the company an “underweight” rating in a research note on Friday, January 26th. Cowen reiterated a “hold” rating and issued a $84.00 target price on shares of PerkinElmer in a research note on Friday, January 26th. Finally, Robert W. Baird reiterated a “buy” rating and issued a $88.00 target price on shares of PerkinElmer in a research note on Friday, January 26th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company’s stock. PerkinElmer has a consensus rating of “Hold” and an average price target of $76.85.
PerkinElmer (NYSE:PKI) last posted its quarterly earnings data on Thursday, January 25th. The medical research company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.03. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The firm had revenue of $641.63 million during the quarter, compared to analysts’ expectations of $619.14 million. During the same quarter in the previous year, the company posted $0.83 EPS. PerkinElmer’s revenue was up 13.2% on a year-over-year basis. equities analysts expect that PerkinElmer will post 3.52 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 10th. Investors of record on Friday, April 13th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.38%. The ex-dividend date is Thursday, April 12th. PerkinElmer’s dividend payout ratio (DPR) is presently 9.66%.
In other PerkinElmer news, insider Frank Anders Wilson sold 103,656 shares of PerkinElmer stock in a transaction on Monday, March 5th. The shares were sold at an average price of $73.94, for a total transaction of $7,664,324.64. Following the completion of the sale, the insider now owns 93,624 shares of the company’s stock, valued at approximately $6,922,558.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Andrew Okun sold 2,324 shares of PerkinElmer stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $75.44, for a total transaction of $175,322.56. Following the sale, the insider now directly owns 8,876 shares of the company’s stock, valued at approximately $669,605.44. The disclosure for this sale can be found here. Insiders sold a total of 108,253 shares of company stock valued at $8,016,623 in the last 90 days. 2.10% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION WARNING: This piece was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3336545/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-perkinelmer-pki-stock-price.html.
PerkinElmer Company Profile
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment develops and offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.